Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP to review Tysabri as PML cases hit 23

This article was originally published in Scrip

Executive Summary

The CHMP is to review the "benefits and risks" of Elan/Biogen Idec's Tysabri (natalizumab) for the treatment of multiple sclerosis, based on an increasing rate of progressive multifocal leucoencephalopathy (PML). The CHMP reported that 23 cases of PML occurred worldwide since launch, higher than the 13 previously disclosed. Biogen Idec shares dropped by 7% on Nasdaq on October 23rd on the news, whereas Elan shares fell by around 17.5% on the NYSE.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC005206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel